Gold sector still trails past peaks in market share and valuation: BofA
In the latest round of daily trades, Cathie Wood’s ARK ETFs have made significant adjustments to their portfolios on Tuesday, September 2, 2025. The trades include major purchases in the biotech sector and a notable reduction in positions in tech and entertainment.
Topping the list of ARK’s daily trades was the sale of 104,713 shares of ROKU INC (NASDAQ:ROKU), valued at over $10 million. This move comes as part of a recent trend for ARK, which has been reducing its stake in the streaming device company, as seen in the previous days’ trades.
On the buying side, ARK’s largest acquisition was 215,278 shares of 10X GENOMICS INC (NASDAQ:TXG), with a total dollar value of approximately $3 million. This purchase reflects ARK’s continued interest in innovative genomics companies.
Another significant trade was the purchase of 56,273 shares of CRISPR THERAPEUTICS AG (NASDAQ:CRSP) through its ARKK ETF, amounting to nearly $2.9 million. This follows a pattern of accumulation in the gene-editing company’s stock by ARK over the past week.
In addition, ARK invested in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), buying 169,686 shares, which represents a value of nearly $1.93 million. This is a continuation of ARK’s bullish stance on Intellia, as the fund has consistently increased its position in the company in recent days.
Conversely, ARK divested a total of 44,861 shares of DRAFTKINGS INC (NASDAQ:DKNG) across three of its ETFs, ARKK, ARKW, and ARKF, with the transactions totaling over $2.15 million. This follows a pattern of selling the online sports betting company’s stock, as observed in the previous trading sessions.
Investors following ARK’s daily trades may note the ETF’s ongoing strategy of focusing on biotech and genomics companies while scaling back on certain tech and entertainment holdings. These trades provide insight into the investment firm’s shifting perspectives on industry trends and individual company prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.